Director/PDMR Shareholding

HALEON

05/09/2025 13:00

RNS Number : 2507Y

Haleon PLC

05 September 2025

 

 

​ Haleon plc: Director/PDMR Shareholding 

 

5 September 2025: Haleon plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs").

This notification sets out the details of the grant of Haleon share awards over Ordinary Shares and American Depositary Shares (ADS) made to PDMRs under the Haleon Share Value Plan and Performance Share Plan.

The Performance Share Plan (Interim) awards are subject to continued employment and performance conditions over the performance period ending on 31 December 2027 (vesting in March 2028). Performance targets were disclosed in the Annual Report and Form 20-F 2024.

The Share Value Plan (Buyout) awards are subject to continued employment.

All awards were made in line with the principles of Haleon's Directors' Remuneration Policy and are subject to malus and clawback provisions.

 

1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Carl Haney
2
Reason for the notification
a)
Position/status
Chief R&D Officer
b)
Initial notification /Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Haleon plc
b)
LEI
549300PSB3WWEODCUP19
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary Shares of £0.01 each
Identification code
GB00BMX86B70
b)
Nature of the transaction
(i) Grant of a conditional award under the Haleon plc Performance Share Plan (Interim)
(ii) Grant of a conditional award under the Haleon plc Share Value Plan (Buyout)
c)
Price(s) and volume(s)
Price(s)
Volume(s)
(i)
Nil
641,096
(ii)
Nil
192,571
d)
Aggregated information
- Aggregated volume
833,667
- Price
Nil
e)
Date of the transaction
4 September 2025
f)
Place of the transaction
Outside a trading venue

 

 

1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
NathalieGerschtein
2
Reason for the notification
a)
Position/status
President North America
b)
Initial notification /Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Haleon plc
b)
LEI
549300PSB3WWEODCUP19
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Haleon plc American Depositary Shares (ADS)
Identification code
US4055521003
b)
Nature of the transaction
(i) Grant of a conditional award under the Haleon plc Performance Share Plan (Interim)
(ii) Grant of a conditional award under the Haleon plc Share Value Plan (Buyout)
c)
Price(s) and volume(s)
Price(s)
Volume(s)
(i)
Nil
244,400
(ii)
Nil
405,911
d)
Aggregated information
- Aggregated volume
650,311
- Price
Nil
e)
Date of the transaction
4 September 2025
f)
Place of the transaction
Outside a trading venue

 

 

Amanda Mellor

Company Secretary

 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

 

For more information, please visit www.haleon.com. 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
DSHBBGDCRDGDGUU